## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 323 Estimated average burden 3235-0287 hours per response..

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Print or Typ	e Responses	)													
Name and Address of Reporting Person * Quinlan Paul T				2. Issuer Name <b>and</b> Ticker or Trading Symbol CymaBay Therapeutics, Inc. [CBAY]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) C/O CYMABAY THERAPEUTICS, INC., 7999 GATEWAY BOULEVARD				3. Date of Earliest Transaction (Month/Day/Year) 01/24/2018							X Officer (give title below) Other (specify below)  General Counsel				
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line)  X_Form filed by One Reporting Person  Form filed by More than One Reporting Person				
NEWARK, CA 94560 (City) (State) (Zip)				Table I - Non-Derivative Securities Acqui						s Acquire	ired, Disposed of, or Beneficially Owned				
1.Title of Se (Instr. 3)	itle of Security 2. Transaction		2A. Deemed Execution Date, i) any (Month/Day/Yea		ate, if Cool (Ins	3. Transaction Code (Instr. 8)		Securities Acquirities Acquiri	uired 5. of (D) Ov Tr	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		neficially (	Ownership of Sorm: Birect (D)	. Nature f Indirect geneficial ownership (nstr. 4)	
Reminder: R	eport on a se	eparate line for each	Table II -	Derivativ	e Se	curities A	cqui	Persons containe form dis	who responed in this formula plays a current ed of, or Bene	m are no ently val ficially O	t required t id OMB cor	o respond	unless the		174 (9-02)
	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	tction 3A. Deemed 4. 5. Number of Execution Date, if Transaction Derivative Expiration Date		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	Ownershi Form of Derivativ Security: Direct (D or Indirect						
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Employee Stock Option (right to buy)	\$ 11.69	01/24/2018		A		250,000		(1)	01/23/2028	Commo	1250 000	\$ 0	250,000	D	
Employee Stock Option (right to buy)	\$ 11.69	01/24/2018		A		50,000		(2)	01/23/2028	Commo Stock	1.50.000	\$ 0	50,000	D	
buy)	ting O	wners													

Donard Donard Name / Address	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Quinlan Paul T						
C/O CYMABAY THERAPEUTICS, INC.			General Counsel			
7999 GATEWAY BOULEVARD						
NEWARK, CA 94560						

# **Signatures**

Paul Quinlan	01/26/2018
Signature of Reporting Person	Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vests as to 1/4 of the underlying shares on December 4, 2018, and vests as to 1/48 of the underlying shares monthly thereafter.
- (2) The option vests as to 1/4 of the underlying shares on January 1, 2019, and vests as to 1/48 of the underlying shares monthly thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

